PMV Pharmaceuticals, Inc.
About PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$77.7M
- Total assets
- $116.6M
- Market cap
- $59.7M
- Operating margin
- -1360.4%
- Net margin
- -1226.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $6.3M
- Operating expenses
- $86.2M
- Operating income
- -$86.2M
- Income tax
- -$2.2M
- Net income
- -$77.7M
- EPS (basic)
- $-1.48
- EPS (diluted)
- $-1.48
Balance sheet
- Total assets
- $116.6M
- Current assets
- $115.2M
- Total liabilities
- $11.8M
- Current liabilities
- $11.4M
- Shareholders’ equity
- $104.7M
Cash flow
- Operating cash flow
- -$73.6M
- Investing cash flow
- $70.2M
- Financing cash flow
- $505.0K
- Net cash flow
- -$2.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $59.7M
- EPS (diluted)
- $-1.48
- Shares outstanding
- 54.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $77.7M.
- Revenue grew 873% from FY2020 to FY2025.
- Trading 39% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review PMV Pharmaceuticals, Inc..
Write a review
News about PMV Pharmaceuticals, Inc.
News & sentiment via Polygon.io
